Compare Stocks

Date Range: 

 United TherapeuticsMirati TherapeuticsEvotecAscendis Pharma A/SArrowhead Pharmaceuticals
SymbolNASDAQ:UTHRNASDAQ:MRTXOTCMKTS:EVTCYNASDAQ:ASNDNASDAQ:ARWR
Price Information
Current Price$181.93$160.06$81.57$118.19$69.29
50-Day Moving Average$181.89$162.36$85.76$129.41$74.89
52-Week Low$98.37$117.68$51.35$109.36$32.86
52-Week High$212.62$249.42$91.26$183.98$93.66
MarketRank™
Overall Score2.51.80.92.62.0
Analysis Score2.53.30.04.52.4
Community Score4.04.94.54.74.5
Dividend Score0.00.00.00.00.0
Ownership Score3.30.80.03.32.5
Earnings & Valuation Score2.50.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$224.38$217.92N/A$192.00$86.45
% Upside from Price Target23.33% upside36.15% upsideN/A62.45% upside24.77% upside
Trade Information
Market Cap$8.15 billion$8.23 billion$6.71 billion$6.36 billion$7.21 billion
Beta0.491.3310.751.26
Average Volume197,323293,916335185,0421,094,898
Sales & Book Value
Annual Revenue$1.48 billion$13.40 million$572.16 million$7.94 million$87.99 million
Price / Sales5.49614.4411.73801.2881.96
Cashflow$12.55 per shareN/A$0.87 per shareN/AN/A
Price / Cash14.50N/A93.68N/AN/A
Book Value$76.40 per share$26.98 per share$10.07 per share$17.94 per share$4.51 per share
Price / Book2.385.938.106.5915.36
Profitability
Net Income$514.80 million$-357,940,000.00$7.14 million$-478,570,000.00$-84,550,000.00
EPS$11.54($7.96)N/A($9.46)($0.84)
Trailing P/E Ratio20.10N/A135.95N/AN/A
Forward P/E Ratio12.58N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins26.92%N/A8.56%-7,700.88%-122.97%
Return on Equity (ROE)12.27%-43.11%7.21%-54.80%-23.64%
Return on Assets (ROA)9.07%-39.31%3.30%-47.37%-18.78%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.23%N/A0.61%N/AN/A
Current Ratio6.66%16.91%2.84%9.42%3.51%
Quick Ratio6.36%16.91%2.78%9.42%3.51%
Ownership Information
Institutional Ownership Percentage94.99%N/AN/A98.29%65.07%
Insider Ownership Percentage12.00%3.12%N/A40.00%3.50%
Miscellaneous
Employees9501993,572482147,000
Shares Outstanding44.80 million51.44 million82.29 million53.83 million104.08 million
Next Earnings Date8/4/2021 (Confirmed)8/5/2021 (Estimated)8/11/2021 (Estimated)8/26/2021 (Estimated)8/5/2021 (Confirmed)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency AssoArrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Asso
us.acrofan.com - July 29 at 8:22 AM
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver DiseaseArrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
finance.yahoo.com - July 29 at 8:22 AM
Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR)Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR)
nasdaq.com - July 17 at 6:30 PM
$50.20 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter$50.20 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter
americanbankingnews.com - July 11 at 2:20 AM
Arrowheads Big Sell-Off Presents Buying Opportunity, According to HC WainwrightArrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
markets.businessinsider.com - July 6 at 6:16 PM
Arrowhead Pharmaceuticals Inc. [ARWR] Stock trading around $63.13 per share: What’s Next?Arrowhead Pharmaceuticals Inc. [ARWR] Stock trading around $63.13 per share: What’s Next?
dbtnews.com - July 6 at 6:16 PM
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sees Large Volume IncreaseArrowhead Pharmaceuticals (NASDAQ:ARWR) Sees Large Volume Increase
americanbankingnews.com - July 6 at 11:43 AM
Mid-day market update: Dow surges over 100 points, Arrowhead Pharmaceuticals shares plummetMid-day market update: Dow surges over 100 points, Arrowhead Pharmaceuticals shares plummet
fxstreet.com - July 2 at 1:04 PM
B.Riley Financial Stick to Their Buy Rating for Arrowhead PharmaceuticalsB.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals
investing.com - July 2 at 1:04 PM
Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis TreatmentArrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatment
thestreet.com - July 2 at 1:04 PM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Making Its Way Up the Stock MarketArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Making Its Way Up the Stock Market
stocksregister.com - July 2 at 1:04 PM
ARWR Jul 2021 80.000 callARWR Jul 2021 80.000 call
uk.finance.yahoo.com - June 28 at 2:01 PM
Arrowhead Presents Additional Clinical Data on...Arrowhead Presents Additional Clinical Data on...
benzinga.com - June 26 at 2:05 PM
H.C. Wainwright Stick to Their Buy Rating for Arrowhead PharmaceuticalsH.C. Wainwright Stick to Their Buy Rating for Arrowhead Pharmaceuticals
investing.com - June 25 at 1:03 PM
Notable ETF Outflow Detected - IWO, RH, DECK, ARWRNotable ETF Outflow Detected - IWO, RH, DECK, ARWR
nasdaq.com - June 25 at 1:03 PM
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research CongressArrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
finance.yahoo.com - June 25 at 8:02 AM
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver CongressArrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
finance.yahoo.com - June 23 at 7:48 AM
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) Shares Plunges -3.46% In A Week – But Can It Keep Rising?Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) Shares Plunges -3.46% In A Week – But Can It Keep Rising?
marketingsentinel.com - June 19 at 2:50 PM
Read This Before Buying Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) SharesRead This Before Buying Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares
nasdaq.com - June 13 at 12:06 PM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): What It’s Worth And What To Do About ItArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): What It’s Worth And What To Do About It
marketingsentinel.com - June 5 at 1:25 PM
Arrowhead Receives $10M Option Exercise Fee From JanssenArrowhead Receives $10M Option Exercise Fee From Janssen
finance.yahoo.com - May 18 at 1:52 PM
Arrowhead Earns $10 Million Option Exercise FeeArrowhead Earns $10 Million Option Exercise Fee
finance.yahoo.com - May 18 at 8:51 AM
Leerink Partners Stick to Their Hold Rating for Arrowhead PharmaceuticalsLeerink Partners Stick to Their Hold Rating for Arrowhead Pharmaceuticals
investing.com - May 9 at 10:13 AM
Arrowhead Pharmaceuticals (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call TranscriptArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:29 PM
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
finance.yahoo.com - May 4 at 7:17 PM
DateCompanyBrokerageAction
7/21/2021Ascendis Pharma A/SSVB Leerink
Lower Price Target
7/14/2021United TherapeuticsArgus
Upgrade
7/8/2021Ascendis Pharma A/SOppenheimer
Reiterated Rating
7/2/2021Arrowhead PharmaceuticalsHC Wainwright
Reiterated Rating
7/2/2021Arrowhead PharmaceuticalsPiper Sandler
Lower Price Target
6/27/2021Arrowhead PharmaceuticalsSVB Leerink
Reiterated Rating
6/21/2021Arrowhead PharmaceuticalsPiper Sandler
Boost Price Target
6/14/2021Ascendis Pharma A/SSVB Leerink
Lower Price Target
6/14/2021Ascendis Pharma A/SWedbush
Lower Price Target
6/14/2021Ascendis Pharma A/SMorgan Stanley
Lower Price Target
6/4/2021Mirati TherapeuticsCitigroup
Upgrade
6/1/2021Ascendis Pharma A/SCanaccord Genuity
Boost Price Target
5/28/2021Ascendis Pharma A/SCredit Suisse Group
Boost Price Target
5/28/2021Ascendis Pharma A/SMorgan Stanley
Boost Price Target
5/24/2021Mirati TherapeuticsOppenheimer
Reiterated Rating
5/17/2021Mirati TherapeuticsOppenheimer
Downgrade
5/11/2021EvotecRoyal Bank of Canada
Upgrade
5/10/2021Mirati TherapeuticsHC Wainwright
Lower Price Target
5/10/2021Mirati TherapeuticsJefferies Financial Group
Upgrade
5/6/2021United TherapeuticsHC Wainwright
Boost Price Target
4/22/2021EvotecDeutsche Bank Aktiengesellschaft
Reiterated Rating
4/8/2021United TherapeuticsJPMorgan Chase & Co.
Boost Price Target
3/30/2021Ascendis Pharma A/SOppenheimer
Downgrade
3/12/2021Ascendis Pharma A/SCanaccord Genuity
Boost Price Target
3/11/2021Ascendis Pharma A/SCredit Suisse Group
Lower Price Target
3/11/2021Ascendis Pharma A/SStifel Nicolaus
Initiated Coverage
3/5/2021EvotecCitigroup
Downgrade
3/1/2021Mirati TherapeuticsOppenheimer
Lower Price Target
3/1/2021Mirati TherapeuticsHC Wainwright
Lower Price Target
2/25/2021United TherapeuticsWedbush
Boost Price Target
2/22/2021United TherapeuticsCredit Suisse Group
Boost Price Target
2/16/2021United TherapeuticsOppenheimer
Boost Price Target
2/8/2021Arrowhead PharmaceuticalsCitigroup
Boost Price Target
2/8/2021Arrowhead PharmaceuticalsB. Riley
Boost Price Target
2/5/2021Arrowhead PharmaceuticalsPiper Sandler
Boost Price Target
2/5/2021Arrowhead PharmaceuticalsChardan Capital
Boost Price Target
2/5/2021Arrowhead PharmaceuticalsHC Wainwright
Boost Price Target
2/1/2021United TherapeuticsHC Wainwright
Upgrade
1/28/2021EvotecRoyal Bank of Canada
Downgrade
1/20/2021United TherapeuticsOppenheimer
Boost Price Target
1/20/2021United TherapeuticsCowen
Boost Price Target
1/20/2021United TherapeuticsLADENBURG THALM/SH SH
Boost Price Target
1/19/2021EvotecDeutsche Bank Aktiengesellschaft
Downgrade
1/15/2021Mirati TherapeuticsHC Wainwright
Lower Price Target
12/21/2020Arrowhead PharmaceuticalsRobert W. Baird
Downgrade
12/17/2020Ascendis Pharma A/SBerenberg Bank
Initiated Coverage
12/16/2020Mirati TherapeuticsCredit Suisse Group
Boost Price Target
12/15/2020Arrowhead PharmaceuticalsUBS Group
Initiated Coverage
12/8/2020Mirati TherapeuticsEvercore ISI
Initiated Coverage
12/8/2020Mirati TherapeuticsJMP Securities
Initiated Coverage
11/24/2020Arrowhead PharmaceuticalsRoyal Bank of Canada
Boost Price Target
11/24/2020Arrowhead PharmaceuticalsCantor Fitzgerald
Boost Price Target
11/24/2020Arrowhead PharmaceuticalsSVB Leerink
Lower Price Target
11/20/2020EvotecRoyal Bank of Canada
Reiterated Rating
11/19/2020Arrowhead PharmaceuticalsSmith Barney Citigroup
Initiated Coverage
11/17/2020Mirati TherapeuticsBank of America
Downgrade
11/17/2020Arrowhead PharmaceuticalsB. Riley
Boost Price Target
11/16/2020Arrowhead PharmaceuticalsRobert W. Baird
Boost Price Target
11/13/2020Ascendis Pharma A/SMorgan Stanley
Boost Price Target
11/12/2020Ascendis Pharma A/SWells Fargo & Company
Boost Price Target
11/12/2020Ascendis Pharma A/SCredit Suisse Group
Boost Price Target
11/12/2020Ascendis Pharma A/SSVB Leerink
Boost Price Target
11/10/2020Mirati TherapeuticsJefferies Financial Group
Downgrade
11/10/2020Mirati TherapeuticsGuggenheim
Downgrade
11/9/2020Mirati TherapeuticsHC Wainwright
Boost Price Target
11/5/2020Mirati TherapeuticsOppenheimer
Boost Price Target
11/5/2020Mirati TherapeuticsPiper Sandler
Boost Price Target
11/2/2020Mirati TherapeuticsHC Wainwright
Lower Price Target
10/29/2020United TherapeuticsWedbush
Boost Price Target
10/29/2020United TherapeuticsOppenheimer
Boost Price Target
10/29/2020Mirati TherapeuticsBarclays
Boost Price Target
10/27/2020Mirati TherapeuticsCredit Suisse Group
Boost Price Target
10/26/2020Mirati TherapeuticsOppenheimer
Boost Price Target
10/26/2020Mirati TherapeuticsSVB Leerink
Boost Price Target
10/26/2020Mirati TherapeuticsThe Goldman Sachs Group
Boost Price Target
10/26/2020Mirati TherapeuticsHC Wainwright
Boost Price Target
10/26/2020Mirati TherapeuticsPiper Sandler
Boost Price Target
10/13/2020Ascendis Pharma A/SMorgan Stanley
Boost Price Target
10/12/2020Arrowhead PharmaceuticalsB. Riley
Boost Price Target
10/12/2020Arrowhead PharmaceuticalsHC Wainwright
Reiterated Rating
10/8/2020Arrowhead PharmaceuticalsPiper Sandler
Boost Price Target
9/30/2020Ascendis Pharma A/SWedbush
Boost Price Target
9/17/2020Arrowhead PharmaceuticalsSVB Leerink
Boost Price Target
9/14/2020United TherapeuticsJPMorgan Chase & Co.
Initiated Coverage
9/14/2020Ascendis Pharma A/SJPMorgan Chase & Co.
Initiated Coverage
9/10/2020EvotecRoyal Bank of Canada
Initiated Coverage
9/1/2020EvotecCitigroup
Initiated Coverage
8/31/2020Ascendis Pharma A/SMorgan Stanley
Boost Price Target
8/28/2020Ascendis Pharma A/SCredit Suisse Group
Boost Price Target
8/24/2020Arrowhead PharmaceuticalsHC Wainwright
Reiterated Rating
7/30/2020United TherapeuticsOppenheimer
Boost Price Target
7/29/2020United TherapeuticsWedbush
Reiterated Rating
7/29/2020Arrowhead PharmaceuticalsChardan Capital
Reiterated Rating
7/15/2020Ascendis Pharma A/SMorgan Stanley
Lower Price Target
6/26/2020Ascendis Pharma A/SWedbush
Initiated Coverage
6/25/2020United TherapeuticsWedbush
Reiterated Rating
6/25/2020United TherapeuticsCredit Suisse Group
Boost Price Target
6/25/2020United TherapeuticsHC Wainwright
Boost Price Target
6/24/2020United TherapeuticsOppenheimer
Initiated Coverage
6/17/2020United TherapeuticsWedbush
Reiterated Rating
6/12/2020United TherapeuticsCowen
Reiterated Rating
5/21/2020Ascendis Pharma A/SMorgan Stanley
Boost Price Target
5/12/2020Arrowhead PharmaceuticalsRoyal Bank of Canada
Initiated Coverage
5/10/2020Arrowhead PharmaceuticalsB. Riley
Reiterated Rating
4/30/2020United TherapeuticsWedbush
Reiterated Rating
4/30/2020United TherapeuticsCredit Suisse Group
Reiterated Rating
3/12/2020EvotecDeutsche Bank Aktiengesellschaft
Reiterated Rating
3/10/2020United TherapeuticsJefferies Financial Group
Upgrade
3/4/2020United TherapeuticsWedbush
Reiterated Rating
8/21/2019EvotecDeutsche Bank Aktiengesellschaft
Upgrade
4/10/2019EvotecDeutsche Bank Aktiengesellschaft
Downgrade
(Data available from 7/31/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.